Biarylcarboxylic Acids and -amides: Inhibition of Phosphodiesterase Type IV versus [3H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret-Reference-Cited by-同舟云学术

Biarylcarboxylic Acids and -amides: Inhibition of Phosphodiesterase Type IV versus [3H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret

Published:1996-01-01 Issue:1 Volume:39 Page:120-125
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Duplantier Allen J.¹,Biggers Michael S.¹,Chambers Robert J.¹,Cheng John B.¹,Cooper Kelvin¹,Damon David B.¹,Eggler James F.¹,Kraus Kenneth G.¹,Marfat Anthony¹,Masamune Hiroko¹,Pillar Joann S.¹,Shirley John T.¹,Umland John P.¹,Watson John W.¹

Affiliation:

1. Central Research Division, Pfizer Inc, Groton, Connecticut 06340

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm9505066

Reference21 articles.

1. Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase

2. Stereospecific binding of the antidepressant rolipram to brain protein structures

3. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast.

4. Inhibitors of Cyclic Nucleotide Phosphodiesterase Isoenzymes—their Potential Utility in the Therapy of Asthma

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PDE4D: A Multipurpose Pharmacological Target;International Journal of Molecular Sciences;2024-07-24

2. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022;Molecules;2022-08-04

3. Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice;Biology;2021-12-20

4. The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors;Pharmacological Reviews;2021-07

5. New insights on the arylpiperazinylalkyl pyridazinone ET1 as potent antinociceptive and anti-inflammatory agent;European Journal of Pharmacology;2020-12